On October 30, 2026, Yong Ben resigned as Chief Medical and Development Officer, effective January 8, 2027, citing no disagreements with company operations. Concurrently, Pedro J. Beltran was appointed Chief Executive Officer. The company operates in the biopharmaceutical industry, focusing on developing treatments for rare genetic diseases.
